Ron Leuty - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Ron Leuty's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Ron Leuty
Verified
Biotech Reporter, San Francisco Business Times
San Francisco
Beats
tech, startups investing, markets digital, businessfinance, stocks
Content
With BioMarin deal, Spruce Biosciences hits reset on rare-disease drug - San Francisco Business Times
By Ron Leuty Verified| San Francisco Business Times Verified The company hopes to push the rare-disease treatment toward FDA approval next year. Four months after ditching its lead drug, a small Peninsula biotech with less than $40 million on hand hopes to rev up investor interest anew with a late-stage drug targeting patients with a deadly rare genetic disease. But investors initially Tuesday didn't take to the reset by Spruce Biosciences Inc.
Itch-fighting biotech Attovia raises $90 million, moves to custom San Carlos space - San Francisco Business Times
By Ron Leuty Verified| San Francisco Business Times Verified Preview this article 1 minThe company's newly built home had been empty for more than a year. A year after raising $105 million, a young biotech company assembled another $90 million and found new digs on the Peninsula as it targets itch, eczema and other conditions where the immune system goes awry. Attovia Therapeutics will use its Series C round, led by Deep Track Capital and involving drugmaker Sanofi SA's venture unit, to push its lead drugs through mid-stage clinical trials.
With BioMarin deal, Spruce Biosciences hits reset on rare-disease drug - San Francisco Business Times
By Ron Leuty Verified| San Francisco Business Times Verified The company hopes to push the rare-disease treatment toward FDA approval next year. Four months after ditching its lead drug, a small Peninsula biotech with less than $40 million on hand hopes to rev up investor interest anew with a late-stage drug targeting patients with a deadly rare genetic disease. But investors initially Tuesday didn't take to the reset by Spruce Biosciences Inc.
Company Info
San Francisco Business Times
The Albany Business Review is a leading business news publication based in Albany, New York. It serves the local business community by providing timely news, data, and networking opportunities. As part of the American City Business Journals network, it covers a wide range of topics, including real estate, finance, and industry developments. The publication offers various services, including newsletters that keep subscribers updated with the latest business intelligence. It also provides data-driven insights to help businesses navigate market conditions. Additionally, the Albany Business Review organizes events and networking opportunities to connect professionals and foster community engagement. Advertising options are available for businesses looking to reach a targeted local audience. Overall, the Albany Business Review is dedicated to supporting business growth and regional economic development.
Albany, New York, United States
+1 704-973-1000
Founded: 1974